Maria Cristina de Oliveira Duque1,2, Érica de Camargo Ferreira E Vasconcellos3, Maria Inês Fernandes Pimentel3, Marcelo Rosandiski Lyra3, Sandro Javier Bedoya Pacheco4, Mauro Celio de Almeida Marzochi3,5, Cláudia Maria Valete Rosalino3,6,7, Armando de Oliveira Schubach3,5,8. 1. Secretaria Municipal de Saúde de Timóteo, Timóteo, Minas Gerais, Brazil. 2. Programa de Pós-Graduação Stricto Sensu em Pesquisa Clínica, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. 3. Laboratório de Pesquisa Clínica e Vigilância em Leishmanioses, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. 4. Departamento de Epidemiologia e Métodos Quantitativos em Saúde, Escola Nacional de Saúde Pública Sérgio Arouca, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. 5. Programa de Produtividade em Pesquisa, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brasília, Distrito Federal, Brazil. 6. Departamento de Otorrinolaringologia e Oftalmologia, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. 7. Programa Jovem Cientista do Nosso Estado, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, Rio de Janeiro, Brazil. 8. Programa Cientista do Nosso Estado, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
Abstract
INTRODUCTION: : Intralesional treatment for cutaneous leishmaniasis has been applied for over 30 years at the Oswaldo Cruz Foundation, Rio de Janeiro, with good therapeutic results and without relevant systemic toxicity. METHODS: Meglumine antimoniate was injected subcutaneously, using a long medium-caliber needle (for example, 30mm × 0.8mm); patients received 1-3 injections, with 15-day intervals. RESULTS: The technique is described in detail sufficient to enable replication. CONCLUSIONS: : The treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate is a simple, effective, and safe technique, which may be used in basic healthcare settings.
INTRODUCTION: : Intralesional treatment for cutaneous leishmaniasis has been applied for over 30 years at the Oswaldo Cruz Foundation, Rio de Janeiro, with good therapeutic results and without relevant systemic toxicity. METHODS: Meglumine antimoniate was injected subcutaneously, using a long medium-caliber needle (for example, 30mm × 0.8mm); patients received 1-3 injections, with 15-day intervals. RESULTS: The technique is described in detail sufficient to enable replication. CONCLUSIONS: : The treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate is a simple, effective, and safe technique, which may be used in basic healthcare settings.
Authors: Carla Oliveira-Ribeiro; Maria Inês Fernandes Pimentel; Liliane de Fátima Antonio Oliveira; Érica de Camargo Ferreira E Vasconcellos; Fatima Conceição-Silva; Armando de Oliveira Schubach; Aline Fagundes; Cintia Xavier de Mello; Eliame Mouta-Confort; Luciana de Freitas Campos Miranda; Claudia Maria Valete-Rosalino; Ana Cristina da Costa Martins; Raquel de Vasconcellos Carvalhaes de Oliveira; Leonardo Pereira Quintella; Marcelo Rosandiski Lyra Journal: PLoS Negl Trop Dis Date: 2021-09-23
Authors: Lucia Regina Brahim; Cláudia Maria Valete-Rosalino; Liliane de Fátima Antônio; Maria Inês Fernandes Pimentel; Marcelo Rosandiski Lyra; Luiz Eduardo de Carvalho Paes; Ananda Dutra da Costa; Iracema Forni Vieira; Cristina Maria Giordano Dias; Maria Cristina de Oliveira Duque; Mauro Celio de Almeida Marzochi; Armando de Oliveira Schubach Journal: Mem Inst Oswaldo Cruz Date: 2017-12 Impact factor: 2.743